Clinical NGS Testing Strategies for Oncology and Rare Disease
This on-demand webinar, recorded April 15, highlights recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.
John Chiang, Director of the Casey Molecular Diagnostics Laboratory at Oregon Health and Science University, discusses a novel targeted next-generation sequencing test for retinal dystrophy. The test has so far been used to interrogate the underlying molecular mechanisms involved in the presentation of RD in more than 700 patients. Dr. Chiang shares details on how the implementation of this test has not only improved his team's understanding of the genes contributing to RD, but has also led to improved patient care and given certain patients the opportunity to be enrolled in clinical trials.
Richard Moore, Sequencing Group Leader at the British Columbia Cancer Agency's Michael Smith Genome Sciences Centre, discusses the use of targeted sequencing at the GSC. In addition to production sequencing for research projects, the GSC recently implemented a College of American Pathologists-accredited diagnostic sequencing pipeline, currently offered for hereditary cancer with other panels under validation.
This webinar is sponsored by WaferGen. Information on the company's targeted resequencing solutions is available here.